İçeriğe geç
akaturk Akademik ölçüm
Giriş Kayıt

Akademisyen

BİROL GÜVENÇ

PROFESÖR

ÇUKUROVA ÜNİVERSİTESİ TIP FAKÜLTESİ DAHİLİ TIP BİLİMLERİ BÖLÜMÜ

  • Ana Dal Sağlık Bilimleri Temel Alanı
  • Yan Dal Hematoloji (İç Hastalıkları)

Kayıtlı çıktılara kısa bakış — ayrıntılar aşağıda.

  • Makale 74
  • Proje 0
  • Kitap 0
  • Bildiri 0
  • Patent 0
  • Sanatsal 0
Scopus (SJR) Q1 16 Q2 20 Q3 23 Q4 8
WoS (JCR) Q1 14 Q2 6 Q3 18 Q4 29
TR Index 5 makale

Alan+yıl+tür normalize OpenAlex yüzdelik — Clarivate ESI / SciVal değildir.

Üst %1 makale 0
Üst %10 makale 3
Ort. yüzdelik 56.2%
Üst %1 payı 0.0%
Üst %10 payı 5.4%

Makaleler

YÖKSİS ve OpenAlex kaynak ayrımıyla makaleler; quartile ve TR Index ile daraltabilirsiniz.

Dizin filtreleri

Toplam 74 yayın

Scopus (SJR)
Q1 16 Q2 20 Q3 23 Q4 8
WoS (JCR)
Q1 14 Q2 6 Q3 18 Q4 29
TR Index
5 makale

Makale listesi

  1. 2024 Retrospective analysis of hemophilia B in Turkey: identifying main characteristics and treatment options. Research and practice in thrombosis and haemostasis DOI 10.1016/j.rpth.2024.102588 YÖKSİS OpenAlex 23.5%
  2. 2024 Therapeutic plasma exchange in critically ill children: 18-year experience of a tertiary care paediatric intensive care unit Australian Critical Care DOI 10.1016/j.aucc.2023.12.006 YÖKSİS SJR Q1 JCR Q1 OpenAlex 77.0%
  3. 2024 Multicentral Retrospective Analysis of Venetoclax-Based Treatments in AML and MDS: A Real-World Study by the Turkish Hematology Network Group. Medicina (Kaunas, Lithuania) DOI 10.3390/medicina60101623 YÖKSİS SJR Q2 JCR Q1 OpenAlex 23.0%
  4. 2023 Clinical Characteristics of Patients with Aggressive Systemic Mastocytosis and Efficacy Analysis of Systemic Therapies: A Monocentric Real-World Experience International Journal of Innovative Research in Medical Science DOI 10.23958/ijirms/vol08-i10/1762 YÖKSİS OpenAlex 13.0%
  5. 2023 The Use of Gemtuzumab Ozogamicin as Salvage Therapy in Patients with Acute Myeloid Leukemia: A Monocentric Real-World Experience Medicina (Kaunas, Lithuania) DOI 10.3390/medicina59030498 YÖKSİS SJR Q2 JCR Q1 OpenAlex 47.4%
  6. 2023 Long-Term Efficacy of Erythropoiesis-Stimulating Agents in Patients with Low-Risk or Intermediate-1-Risk Myelodysplastic Syndrome: Multicenter Real-Life Data Turkish Journal of Hematology DOI 10.4274/tjh.galenos.2023.2022.0437 YÖKSİS TR Index SJR Q3 JCR Q3 OpenAlex 3.0%
  7. 2023 Clinical Characteristics and Outcomes of Cancer Cases Among Syrian Refugees From Southern Turkey. JAMA network open DOI 10.1001/jamanetworkopen.2023.12903 YÖKSİS OpenAlex üst %10 OpenAlex 94.5%
  8. 2023 Efficacy of Bendamustine, Pomalidomide, and Dexamethasone (BPD) Regimen in Relapsed/Refractory Extramedullary Myeloma: A Retrospective Single-Centre Study, Real-Life Experience Hematology Reports DOI 10.3390/hematolrep15030048. YÖKSİS OpenAlex 70.6%
  9. 2023 Unmet clinical needs and challenges in the management of acute leukemia in Turkey: a modified Delphi study Future Medicine Ltd DOI 10.2217/fon-2022-0984 YÖKSİS SJR Q1 JCR Q2 OpenAlex 66.9%
  10. 2023 MM-243 Addressing Multiple Myeloma in Turkey: A Nationwide Survey by the Turkish Hematology Network Group Highlights Opportunities and Challenges Elsevier BV DOI 10.1016/S2152-2650(23)01422-2 YÖKSİS SJR Q3 JCR Q2
  11. 2022 Real-world treatment patterns and clinical outcomes in patients with AML unfit for first-line intensive chemotherapy * Informa UK Limited DOI 10.1080/10428194.2021.2002321 YÖKSİS SJR Q2 JCR Q3 OpenAlex üst %10 OpenAlex 94.2%
  12. 2022 Impact of COVID-19 on Outcomes of Patients with Hematologic Malignancies: A Multicenter, Retrospective Study. Mediterranean journal of hematology and infectious diseases DOI 10.4084/MJHID.2022.074 YÖKSİS SJR Q2 JCR Q2 OpenAlex 63.9%
  13. 2022 The Clinical Efficacy of Epoetin Alfa and Darbepoetin Alfa in Patients with Low-Risk or Intermediate-1-Risk Myelodysplastic Syndrome: Retrospective Multi-center Real-Life Study. Indian journal of hematology & blood transfusion DOI 10.1007/s12288-021-01458-1 YÖKSİS SJR Q3 JCR Q4 OpenAlex 63.6%
  14. 2022 Healthcare resource utilization trends in patients with acute myeloid leukemia ineligible for intensive chemotherapy receiving first-line systemic treatment or best supportive care: A multicenter international study. European journal of haematology DOI 10.1111/ejh.13769 YÖKSİS SJR Q1 JCR Q3 OpenAlex 79.2%
  15. 2022 The effect of comorbidities on the choice of tyrosine kinase inhibitors in patients with chronic myeloid leukemia. International journal of hematologic oncology DOI 10.2217/ijh-2021-0010 YÖKSİS SJR Q3 OpenAlex 89.6%
  16. 2021 Efficacy and safety of ruxolitinib in patients with myelofibrosis: a retrospective and multicenter experience in Turkey TURKISH JOURNAL OF MEDICAL SCIENCES DOI 10.3906/sag-1812-70 YÖKSİS TR Index SJR Q3 JCR Q3 OpenAlex 19.5%
  17. 2020 Study for the Diagnostic Screening of Paroxysmal Nocturnal Hemoglobinuria in Older Patients with Unexplained Anemia and/or Cytopenia Clinical Laboratory DOI 10.7754/Clin.Lab.2020.191218. YÖKSİS SJR Q3 JCR Q4 OpenAlex 8.3%
  18. 2019 Crizanlizumab Versus Placebo, with or without Hydroxyurea/Hydroxycarbamide, in Adolescent and Adult Patients with Sickle Cell Disease and Vaso-Occlusive Crises: A Randomized, Double-Blind, Phase III Study (STAND) American Society of Hematology DOI 10.1182/blood-2019-125775 YÖKSİS SJR Q1 JCR Q1
  19. 2019 Study for the diagnostic screening of paroxsymal nocturnal hemoglobinuria in Turkey: Prospective multicentric evaluation of suspected patients Transfusion and Apheresis Science DOI 10.1016/j.transci.2019.08.021 YÖKSİS SJR Q3 JCR Q4 OpenAlex 8.5%
  20. 2018 Outcomes with frontline nilotinib treatment in Turkish patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase. Hematology (Amsterdam, Netherlands) DOI 10.1080/10245332.2018.1444919 YÖKSİS SJR Q3 JCR Q4 OpenAlex 83.7%

Akademisyenlere dön